RxDoctor Payments Data

Allison Vanputte, NP

Adult Health · Rochester, NYNPI 1811167349

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 63.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $263 and has fallen 93.3% since, to $18 in 2024.

$522in general payments, 2019–2025

Across 44 payments — averaging $11.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$333
  • AbbVie$82
  • Bristol Myers Squibb$47
  • Braintree Laboratories, Inc.$47
  • Takeda Pharmaceuticals U.S.A., Inc.$13

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$522 in reported general payments places this provider in the 55th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$17,041
Medicare patients
138
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab15$101,383
LinzessLinaclotide85$83,336
Mesalamine69$32,263
TrulancePlecanatide46$28,108
SutabSod Sulf/Pot Chloride/Mag Sulf169$26,703
Ursodiol69$18,367
Famotidine719$13,587
Mesalamine DrMesalamine30$10,180
Esomeprazole Magnesium311$9,397
Sucralfate114$9,076
Mesalamine ErMesalamine23$7,905
Dexlansoprazole DrDexlansoprazole34$7,557
ErythromycinErythromycin Base25$7,485
Colesevelam Hcl86$6,189
Pantoprazole Sodium552$5,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$82$83,33685 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$333$28,10846 claims
Braintree Laboratories, Inc.Sutab$47$26,703169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,828 adult health providers in New York.

Other adult health in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →